Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Significant Increase in Short Interest

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 5,120,000 shares, an increase of 12.0% from the November 30th total of 4,570,000 shares. Based on an average trading volume of 805,900 shares, the days-to-cover ratio is currently 6.4 days. Currently, 9.3% of the shares of the stock are sold short.

Agios Pharmaceuticals Trading Down 2.8 %

Shares of NASDAQ AGIO opened at $33.40 on Monday. Agios Pharmaceuticals has a 1-year low of $20.96 and a 1-year high of $62.58. The company has a 50-day moving average of $48.89 and a two-hundred day moving average of $46.17. The company has a market cap of $1.90 billion, a PE ratio of 2.94 and a beta of 0.80.

Analysts Set New Price Targets

AGIO has been the topic of several analyst reports. Raymond James reaffirmed an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Royal Bank of Canada upped their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, Scotiabank increased their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $56.33.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Exome Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at $2,941,000. Franklin Resources Inc. bought a new position in Agios Pharmaceuticals in the third quarter valued at about $1,499,000. Geode Capital Management LLC boosted its holdings in Agios Pharmaceuticals by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after acquiring an additional 6,101 shares during the last quarter. Frazier Life Sciences Management L.P. increased its position in Agios Pharmaceuticals by 19.7% in the third quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock worth $46,392,000 after purchasing an additional 172,180 shares during the period. Finally, XTX Topco Ltd raised its holdings in Agios Pharmaceuticals by 56.2% during the 3rd quarter. XTX Topco Ltd now owns 8,329 shares of the biopharmaceutical company’s stock worth $370,000 after purchasing an additional 2,996 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.